Evaluated across 1,035 regulated documents.
At DIA 2026, Clinplex presented a multi-framework regulatory and quality gap-detection methodology evaluated across SOPs, CAPAs, deviations, audit records, CMC submissions, validation packages and preclinical documents. 96% gap-detection accuracy against SME review.
Gap-detection accuracy
Measured against SME-panel ground truth.
More gaps surfaced
12.3 regulatory gaps per SOP vs 4.1 under single-framework review.
Less assessment time
Reduction in cross-framework regulatory assessment time.
Critical-tier sensitivity
Agreement with SME review on Critical findings.
How we tested it.
A 1,035-document regulated corpus drawn from biologics, small-molecule and CDMO operating environments.
Human review was part of the benchmark.
Multi-framework analysis found substantially more.
| Performance | Single-framework review | Clinplex multi-framework |
|---|---|---|
| Average gaps per SOP | 4.1 | 12.3 |
| Critical-tier sensitivity | 0.71 | 0.98 |
| Specificity | 0.88 | 0.94 |
| Cross-document linkage | Not evaluated | SOP → CAPA mapped |
Why 3× more findings?
We tested consistency,
not one successful output.
Detailed reproducibility protocol and evaluation artifacts are available under NDA.
Study limitations.
The reported evaluation covered selected organizations, regulatory classes and document types. The results should not be interpreted as universal performance across every organization, document type or regulatory framework. Broader cross-organizational evaluation and longitudinal characterization remain ongoing work.
See what the result actually looks like.
Every Clinplex finding carries the full evidentiary chain — from the source record to the proposed fix.
Review the underlying work.
AI-Enabled Multi-Framework Regulatory and Quality Gap Detection for Pharmaceutical Operations Across the Product Lifecycle
Now run it on
your own records.
One closed deviation, its CAPA and the governing SOP. Ranked gaps with citations and a drafted remediation. Free.